Management of Grass Pollen Allergy with 5-Grass Pollen Tablet: Results of a 2-Year Real-Life Study

Abstract

IntroductionAllergen immunotherapy is the only treatment option for allergic rhinitis with disease-altering potential. It was the objective of this study to assess the effectiveness and tolerability of a 5-grass pollen tablet in a large population of non-selected grass pollen allergic patients, i.e. patients with different clinical profiles in daily clinical practice.MethodsIn a 2-year, prospective, open-label, multicenter, non-controlled, observational study patients were included from 327 centers across Germany. Rhinoconjunctivitis symptoms, symptomatic medication intake and adverse events were recorded.ResultsA total of 1482 patients aged 4–75 years were included. During the 2-year period of 5-grass pollen tablet therapy, mean rhinoconjunctivitis score decreased significantly in the overall study population by 65.5% (P < 0.001). The percentage of patients taking symptomatic medication decreased from 83.8% to 42.7%. Mean 2-year improvements in rhinoconjunctivitis scores and decreases in the percentage of patients taking symptomatic medication were broadly similar in adults, adolescents and children, in patients with polyallergy versus monoallergy, and in patients with/without asthma. Among polyallergic patients, concomitant application of another specific immunotherapy did not impair treatment outcomes. Adverse drug reactions, predominantly affecting the local application area, occurred in 15.4% of the overall patient population (n = 229). No cases of anaphylaxis or epinephrine use were documented.ConclusionThis study indicates that sublingual immunotherapy with the 5-grass pollen tablet is well tolerated and provides sustained effectiveness over 2 years in patients with different clinical profiles, producing a significant decrease in allergic symptoms and a reduction in the use of symptomatic medication.FundingStallergenes GmbH.

Clinical performance of house-dust-mite-specific subcutaneous immunotherapy in a postmarket noninterventional setting

“…Despite the low inclusion figures, clinical effects on allergic symptoms were already detected that are comparable to a recent study presenting data after 2 years of treatment [4]. The use of symptomatic medication was also considerably reduced.…”

Ultra‐short‐course booster is effective in recurrent grass pollen‐induced allergic rhinoconjunctivitis

“…At the last visit (Visit 7), the state of health of the patients in both study groups was evaluated by patients and investigators individually using a scale from 1 to 4, where 1=“significantly better,” 2=“slightly better,” 3=“unchanged” and 4=“worse,” comparing the year before AIT treatment and the year of the AIT treatment …”

Ultra-Short-Course Booster Allergen Immunotherapy

“…The above mentioned results were supported by the patients' assessment of their state of health in 2015 in comparison with that in the previous year using the following scale: 'significantly better', 'slightly better', 'unchanged', and 'worse' [21]. The great majority (92%) of booster AIT patients evaluated their state of health in 2015 as significantly or slightly better.…”